ACLARUBICIN HYDROCHLORIDE manufacturers
|
| | ACLARUBICIN HYDROCHLORIDE Basic information |
| Product Name: | ACLARUBICIN HYDROCHLORIDE | | Synonyms: | aclacinomycinahydrochloride;aclacinon;n-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyrano;syl)oxy)-2,5,7-trihydroxy-,methylester,hydrochloride,(1r-(1-alpha,2-beta,4;1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-l-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-l-lyxo;ACLARUBICIN HYDROCHLORIDE;1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]-3-(dimethylamino)-α-L-lyxo-hexopyranosyl]oxy]-, meth;1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]-3-(dimethylamino)-α-L-lyxo-hexopyranosyl]oxy]-, methyl ester, hydrochloride, [1R-(1α,2β,4β)]- | | CAS: | 75443-99-1 | | MF: | C42H54ClNO15 | | MW: | 848.33 | | EINECS: | 278-209-3 | | Product Categories: | API | | Mol File: | 75443-99-1.mol |  |
| | ACLARUBICIN HYDROCHLORIDE Chemical Properties |
| Melting point | 151-153℃ | | Boiling point | 898℃ | | Fp | >110°(230°F) | | storage temp. | 2-8°C | | solubility | Soluble in DMSO or DMF at 25mg/ml |
| Hazard Codes | T | | Risk Statements | 23/24/25 | | Safety Statements | 36/37/39-45 | | RIDADR | 3249 | | RTECS | QI9283500 | | HazardClass | 6.1(a) | | PackingGroup | II |
| | ACLARUBICIN HYDROCHLORIDE Usage And Synthesis |
| Definition | ChEBI: Aclarubicin hydrochloride is an anthracycline. | | Biological Activity | Aclacinomycin A hydrochloride (Aclarubicin hydrochloride) is a fluorescent molecule and the first non-peptidic inhibitor discovered to have discrete specificity for the CTRL (chymotrypsin-like) activity of the 20S proteasome. It is also a dual inhibitor of topoisomerase I and II (topoisomerase I and II). It is an effective anthracycline chemotherapeutic agent for blood cancer and solid tumor related research. | | in vitro | Aclacinomycin A could efficiently enter living cells and emit fluorescence in situ . Aclacinomycin A (10 μM for 15 min) is sufficient for clear detection of fluorescence in most of the cultured cells. Aclacinomycin A treatment (10 μM Acla for 15 min) results in approximately 20% dead (or nearly dead) cells.
Aclacinomycin A (Aclarubicin) effectively induces incorporation of exon 7 into SMN2 transcripts from the endogenous gene in type I SMA fibroblasts as well as into transcripts from a SMN2 minigene in the motor neuron cell line NSC34 .
| | in vivo | Aclarubicin hydrochloride(Aclacinomycin A) is very well absorbed in mice, rats, and dogs after its oral administration. The oral LD 50 (76.5 mg/kg) is about twice the iv LD 50 (35.6 mg/kg) in mice [4 .
Aclacinomycin A ( 0.75-6 mg/kg, ip daily) dose-dependently exhibits tumor growth in mice-based Leukemia P-388 model [4 .
| Animal Model: | DBA/2, CDF 1 ( BALB/c×DBA/2) mice with Leukemia P-388 [4 . | | Dosage: | 0.75 mg/kg, 1.5 mg/kg, 3 mg/kg, 6 mg/kg. | td> | Administration: | Intraperit oneal administration daily for 10 days starting 3 hr after transplantation. | | Result: | Inhibited tumor growth. | | | target | 20S proteasome.
Topoisomerase I and II. |
| | ACLARUBICIN HYDROCHLORIDE Preparation Products And Raw materials |
|